

# Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

## CD20 (E3N7O) XP® Rabbit mAb

RRID:AB\_2943602

Type: Antibody

### Proper Citation

Cell Signaling Technology Cat# 70168, RRID:AB\_2943602

### Antibody Information

**URL:** [http://antibodyregistry.org/AB\\_2943602](http://antibodyregistry.org/AB_2943602)

**Proper Citation:** Cell Signaling Technology Cat# 70168, RRID:AB\_2943602

**Target Antigen:** CD20

**Host Organism:** rabbit

**Clonality:** recombinant monoclonal

**Comments:** Applications: WB, IP, IHC-Bond, IHC-P, IF-F

**Antibody Name:** CD20 (E3N7O) XP® Rabbit mAb

**Description:** This recombinant monoclonal targets CD20

**Target Organism:** rat, mouse

**Clone ID:** E3N7O

**Antibody ID:** AB\_2943602

**Vendor:** Cell Signaling Technology

**Catalog Number:** 70168

**Record Creation Time:** 20250820T052300+0000

**Record Last Update:** 20250820T212712+0000

### Ratings and Alerts

No rating or validation information has been found for CD20 (E3N7O) XP® Rabbit mAb.

No alerts have been found for CD20 (E3N7O) XP® Rabbit mAb.

## Data and Source Information

**Source:** [Antibody Registry](#)

## Usage and Citation Metrics

We found 4 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Yu L, et al. (2025) Tumor-derived arachidonic acid reprograms neutrophils to promote immune suppression and therapy resistance in triple-negative breast cancer. *Immunity*, 58(4), 909.

Tang Z, et al. (2025) Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures. *Cancer cell*, 43(6), 1025.

Zhang Y, et al. (2024) CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis. *Cancer cell*, 42(8), 1370.

Chandra V, et al. (2024) Gut epithelial Interleukin-17 receptor A signaling can modulate distant tumors growth through microbial regulation. *Cancer cell*, 42(1), 85.